Back to Sites Chiangrai Prachanukroh Hospital Site Number 5116 Address Chiang Rai Regional Hosp. CRS Chiangrai Prachanukroh Hospital 1039 Sathanpayaban Road Chiang Rai, Chiang Rai 57000 Thailand IMPAACT Members at this Site Suree KaewPanan CAB Member Wannipha Yenjal Clinical Research Assistant Pra-Ornsuda Sukrakanchana CRS Coordinator Supaporn Utsaha CRS Coordinator Gonzague J. Jourdain CRS Leader Pacharee Kantipong CRS Leader Jane E. Bupp DAIDS PO Jullapong Achalapong Investigator Chulapong Chanta Investigator Rawiwan Hansudewechakul Investigator Pradthana Ounchanum Investigator Chaiporn Kamluang Local Laboratory Yupawan Thaweesombat Pharmacist of Record Ruethai Wongchai Research Assistant Sangdao Somsri Staff Suporn Watanaporn Staff Tim Cressey Study Coordinator Chaniporn Yodsuwan Study Coordinator Studies at this Site 1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival) DAIDS Number 10779 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed P1026S: PK in Pregnancy DAIDS Number 10040 Research Area Treatment Study Status Closed to Follow Up P1083: Kaletra/Aluvia PK study DAIDS Number 10787 Research Area Treatment Study Status Concluded P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Treatment Study Status Closed to Accrual P1097: Raltegravir PK Study DAIDS Number 11790 Research Area Treatment Study Status Concluded P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure Study Status Enrolling IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents DAIDS Number 34150 Research Area Treatment IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Treatment Study Status Enrolling Pagination Current page 1 Page 2 Next page Next
1077HS: HAART Standard Version of the PROMISE Study (Maternal & Infant Survival) DAIDS Number 10779 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed
P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Treatment Study Status Closed to Accrual
P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure Study Status Enrolling
IMPAACT 2010: VESTED DAIDS Number 30129 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents DAIDS Number 34150 Research Area Treatment
IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age DAIDS Number 38504 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Treatment Study Status Enrolling